AMGN : Analysis & Opinions

  • Showing 1-100 of 124 items
  • 1
  • 2
  • >>
  1. Amgen Beats on Q4 Earnings & Revenues, Maintains Outlook - Analyst ...

    January 28, 2015
    Amgen continued with its strong performance in Q4 with the company surpassing expectations yet again.
  2. Pfizer Beats on Q4 Earnings, Guides Below Expectations - Analyst ...

    January 27, 2015
    Pfizer's (PFE) 2015 guidance disappointed with results expected to be hit by genericization as well as unfavorable currency ...
  3. TrovaGene Partners with Leading Cancer Research Institutes - ...

    January 26, 2015
    TrovaGene Inc. (TROV) recently announced a number of collaborations with eminent research institutes around the world.
  4. Will Amgen (AMGN) Keep the Earnings Streak Alive in 4Q? - Analyst ...

    January 23, 2015
    Amgen (AMGN) has consistently surpassed earnings expectations. However, it looks like the company could miss in the fourth ...
  5. Medivation and Astellas Report TERRAIN Data on Xtandi - Analyst ...

    January 23, 2015
    Medivation Inc. (MDVN) and partner Astellas Pharma Inc.'s (ALPMY) Xtandi met the primary endpoint in a phase II study (TERRAIN) ...
  6. UCB's New Epilepsy Drug Under Review in the U.S., EU - Analyst ...

    January 22, 2015
    UCB S.A. (UCBJF) announced that its investigational antiepileptic candidate, brivaracetam, has been accepted for review in ...
  7. Curis Up on Immuno-Oncology Agreement with Aurigene - Analyst ...

    January 22, 2015
    Curis (CRIS) inked an exclusive collaboration agreement with Aurigene Discovery Technologies Limited, an independent, wholly ...
  8. BioMarin to Raise Funds to Finance Prosensa Acquisition - Analyst ...

    January 22, 2015
    BioMarin (BMRN) will be raising approximately $792.6 million through the issuance of the shares in order to finance the Prosensa ...
  9. Novartis' Psoriasis Drug Cosentyx Gets FDA Approval - Analyst ...

    January 22, 2015
    Novartis (NVS) announced that the FDA has approved Cosentyx for the treatment of moderate-to-severe plaque psoriasis in adult ...
  10. Keryx to Raise $110 Million Through Issuance of Shares - Analyst ...

    January 22, 2015
    Keryx (KERX) will be raising $110 million through the issuance of the shares with plans to invest the funds on the ongoing ...
  11. Bristol-Myers Makes Leadership Changes, Names New CEO - Analyst ...

    January 21, 2015
    Bristol-Myers Squibb Company announced certain leadership changes approved by its board of directors including the appointment ...
  12. Hospira's Plum 36O Infusion System Gets FDA Clearance - Analyst ...

    January 21, 2015
    Hospira, Inc. (HSP) announced that it has received 510(k) regulatory clearance for the Plum 360 infusion system with Hospira ...
  13. Alnylam to Raise $450 Million Through Issuance of Shares - Analyst ...

    January 21, 2015
    Alnylam (ALNY) will be raising $450 million through the issuance of shares with plans to invest the funds across its pipeline.
  14. Affymetrix Hits 52-Week High on Strong Top-Line Growth - Analyst ...

    January 21, 2015
    Shares of Affymetrix Inc. (AFFX) scaled a new 52-week high of $11.89 on Jan 20, eventually closing at $11.65.
  15. Biotech Stock Roundup: EU Approvals for AbbVie & Celgene Drugs, ...

    January 21, 2015
    The hepatitis C virus (HCV) pricing battle is heating up with Gilead (GILD) signing on with quite a few PBMs and health care ...
  16. Novartis' Cosentyx Approved in Europe for Plaque Psoriasis - ...

    January 20, 2015
    Positive news flowed in for Novartis AG (NVS) when the European Commission approved its biologic Cosentyx (secukinumab) for ...
  17. Supernus Downgraded as Lead Drugs Face Patent Challenges - Analyst ...

    January 20, 2015
    Zacks Investment Research downgraded Supernus Pharmaceuticals (SUPN) to a Zacks Rank #4 (Sell) on Jan 20.
  18. Sanofi and Boehringer Ingelheim Ink Strategic Deal - Analyst ...

    January 20, 2015
    Sanofi (SNY) announced that it has entered into a strategic agreement with Boehringer Ingelheim
  19. J&J Beats on Q4 Earnings, Revenues Hit by Currency - Analyst ...

    January 20, 2015
    J&J's fourth quarter results were mixed with the company beating on earnings and missing on revenues.
  20. AbbVie Gains EU Approval for Hepatitis C Virus Treatment - Analyst ...

    January 19, 2015
    Approval was expected as the CHMP had provided a positive opinion late last year.
  21. ZIOPHARM, Intrexon Ink CAR T Deal with MD Anderson - Analyst ...

    January 16, 2015
    ZIOPHARM Oncology (ZIOP) and Intrexon (XON) inked a broad exclusive licensing agreement with the University of Texas MD Anderson ...
  22. Amgen (AMGN) Reveals Mixed Results from Vectibix Studies - Analyst ...

    January 16, 2015
    Amgen (AMGN) announced new data from the phase II PEAK study and the phase III PRIME study on Vectibix.
  23. Hospira Submits Retacrit Regulatory Application to the FDA - ...

    January 16, 2015
    Hospira, Inc. (HSP) announced that it has submitted a Biologics License Application looking to get Retacrit approved in the ...
  24. The Biggest Biotech Companies

    January 15, 2015
    These biotech firms want to revolutionize medicine. If successful, they may see high profits, but investing in these companies ...
  25. AstraZeneca Announces Encouraging Data from Brilinta Study - ...

    January 15, 2015
    AstraZeneca (AZN) announced encouraging top-line results from the PEGASUS-TIMI 54 study on Brilinta.
  26. Amgen Maintains 2015 View, Expects Several Drug Launches - Analyst ...

    January 14, 2015
    Amgen (AMGN) said that it is maintaining its 2015 revenue guidance.
  27. Biotech Stock Roundup: Shire to Acquire NPSP, Celgene & Pharmacyclics ...

    January 14, 2015
    Preliminary fourth quarter results and expectations for 2015 were key highlights in the biotech sector.
  28. Illumina Partners Lockheed Martin for Genomics Solutions - Analyst ...

    January 13, 2015
    Illumina Inc. (ILMN) recently formed a strategic alliance with Lockheed Martin (LMT).
  29. Perrigo/Ferrara Candy Ink Supply Deal for Gummy Products - Analyst ...

    January 13, 2015
    The Nutritionals unit at Perrigo Company (PRGO) has inked a five-year supply agreement with Ferrara Candy Company.
  30. Biogen to Acquire Convergence, Expand Pain Pipeline - Analyst ...

    January 13, 2015
    Biogen's (BIIB) upcoming acquisition of Convergence should strengthen its pain pipeline.
  31. Aegerion Reveals Preliminary 2014 Results and 2015 Outlook - ...

    January 13, 2015
    Aegerion Pharmaceuticals, Inc. (AEGR) announced preliminary 2014 net product sales estimates and an outlook for 2015 besides ...
  32. Regeneron/Sanofi Seek PCSK9 Drug Praluent Approval in EU - Analyst ...

    January 12, 2015
    Regeneron and Sanofi announced that the Marketing Authorisation Application for Praluent has been accepted by the European ...
  33. Emergent BioSolutions Provides Preliminary 2014 Results - Analyst ...

    January 12, 2015
    Emergent BioSolutions (EBS) announced preliminary results for 2014 and provided an outlook for 2015.
  34. Conatus Announced Results from Emricasan Studies - Analyst Blog

    January 12, 2015
    Conatus (CNAT) announced top-line results from studies on emricasan in organ-impaired patients.
  35. AMAG Provides 2014 Preliminary Results & 2015 Guidance - Analyst ...

    January 12, 2015
    AMAG Pharmaceuticals (AMAG) provided preliminary results for the fourth quarter and full year 2014 as well as its 2015 financial ...
  36. Vertex Pharmaceuticals' Kalydeco Remains in Focus in 2015 - ...

    January 12, 2015
    Vertex Pharmaceuticals (VRTX) provided an update on its cystic fibrosis pipeline and issued preliminary financial guidance ...
  37. UCB Initiates Phase III Psoriasis Study on Cimzia with Dermira ...

    January 9, 2015
    UCB S.A. (UCBJF) and Dermira finished dosing the first set of patients in a phase III development program on Cimzia for moderate-to-severe ...
  38. 3 Pharma Stocks That Soared Past Pfizer in 2014 - Analyst Blog

    January 9, 2015
    Like many of its pharma counterparts, Pfizer's (PFE) top-line remained under pressure due to generic competition for several ...
  39. Novartis' Biosimilar of Neupogen Gets Favorable Opinion - Analyst ...

    January 8, 2015
    Novartis' (NVS) generic arm, Sandoz, announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory ...
  40. Biotech Stock Roundup: Kite Flies High on Amgen Deal, Isis Soars ...

    January 7, 2015
    Collaborations and agreements continued to make headlines in the biotech sector with companies like Gilead (GILD), Amgen ...
  41. Kite Pharma Up on Amgen Cancer Immunotherapy Tie-Up - Analyst ...

    January 6, 2015
    Amgen Inc. (AMGN) and Kite Pharma (KITE) are tying up for the development and commercialization of chimeric antigen receptor ...
  42. Amgen Upgraded to Strong Buy; is it in Your Portfolio? - Analyst ...

    January 5, 2015
    On Jan 3, Zacks Investment Research upgraded Amgen (AMGN) to a Zacks Rank #1 (Strong Buy).
  43. Tekmira Jumped Following Update on its Oncology Candidate - Analyst ...

    January 2, 2015
    Tekmira Pharmaceuticals' (TKMR) shares increased almost 9% after it provided updates from phase I/II studies on TKM-PLK1.
  44. Teva's Granix Label Expanded to Include Self-Administration - ...

    December 30, 2014
    Teva Pharmaceutical Industries Ltd. (TEVA) announced that an additional administration option for Granix injection has been ...
  45. Synthetic Biologics Unveils Top-Line Safety Data on SYN-004 - ...

    December 29, 2014
    Synthetic Biologics, Inc. (SYN) announced positive results from the first safety and tolerability review in a phase Ia study ...
  46. Kite Pharma Files IND for Non-Hodgkin Lymphoma Drug - Analyst ...

    December 29, 2014
    Kite Pharma, Inc. (KITE) submitted an investigational new drug application to the FDA for KTE-C19 for refractory aggressive ...
  47. Can-Fite Enrols First Patient for a Liver Cancer Study - Analyst ...

    December 29, 2014
    Can-Fite (CANF) announced that it started dosing patients for a phase II study on CF 102.
  48. BioLineRx Out-Licences Skin Lesion Treatment Candidate - Analyst ...

    December 26, 2014
    BioLineRx (BLRX) out-licenced BL-5010 in Europe, Australia and additional countries to Omega Pharma.
  49. BioCryst Rises on Positive Ebola Candidate Results - Analyst ...

    December 26, 2014
    Shares of BioCryst Pharmaceuticals (BCRX) rallied 6.9% after the announcement of results from a study on its Ebola virus ...
  50. Stock Market News for December 26, 2014 - Market News

    December 26, 2014
    Markets ended modestly higher on Wednesday’s abbreviated trading session banking on initial claims dropping to a seven-week ...
  51. After Gilead Sciences, Is it Time to Sell Biotech Stocks? - Analyst ...

    December 26, 2014
    Gilead Sciences Inc. has plunged approximately 15.8% after pharmacy benefit manager Express Scripts entered into an agreement ...
  52. 4 Biotech Stocks that Doubled in 2014 - Analyst Blog

    December 26, 2014
    Promising pipeline candidates, progress on the regulatory front and interesting research platforms helped these 4 biotech ...
  53. Cytokinetics Rises After Extending Astellas Agreement - Analyst ...

    December 24, 2014
    Cytokinetics (CYTK) shares jumped after announcing an amendment to its collaboration with Astellas.
  54. Endo/BioDelivery File Regulatory Application for Pain Drug - ...

    December 24, 2014
    Endo International along with its partner BioDelivery Sciences International, Inc. announced the submission of a new drug ...
  55. Stock Market News for December 24, 2014 - Market News

    December 24, 2014
    Benchmarks mostly settled in the green on Tuesday banking on better-than-expected revision to third quarter GDP numbers
  56. Achillion Gains on Positive Results from its HCV Candidates - ...

    December 23, 2014
    Achillion Pharmaceuticals (ACHN) gained more than 9% after announcing encouraging results from its HCV candidates.
  57. Medivation Licenses CureTech's Cancer Drug Pidilizumab - Analyst ...

    December 23, 2014
    Medivation (MDVN) exercised its option for pidilizumab (CT-011) from CureTech, Ltd. under the terms of the license agreement ...
  58. Orexigen's Obesity Drug Mysimba Gets CHMP Nod - Analyst Blog

    December 22, 2014
    The CHMP gave a positive opinion on the approval of Orexigen's (OREX) weight loss drug, Mysimba.
  59. AstraZeneca's Lynparza Cleared in U.S. for Ovarian Cancer - Analyst ...

    December 22, 2014
    The FDA has cleared AstraZeneca's (AZN) Lynparza as a monotherapy for the maintenance treatment of adults suffering from ...
  60. AbbVie's All-Oral, Interferon-Free HCV Treatment Approved - Analyst ...

    December 22, 2014
    AbbVie's (ABBV) Viekira Pak will be entering the HCV market which is currently dominated by Gilead.
  61. Celgene Gets Positive CHMP Recommendation for Revlimid - Analyst ...

    December 22, 2014
    Celgene Corporation announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has rendered ...
  62. Agenus Jumps on Positive Data from Shingles Candidate - Analyst ...

    December 19, 2014
    Shares of Agenus Inc. (AGEN) jumped after its partner GlaxoSmithKline (GSK) announced encouraging results on HZ/su.
  63. Seattle Genetics Initiates Phase Ib Study on Leukemia Drug - ...

    December 19, 2014
    Seattle Genetics, Inc. (SGEN) has initiated a phase Ib study on SGN-CD33A for newly diagnosed acute myeloid leukemia.
  64. Halozyme Up on Collaboration and Licensing Deal with J&J - Analyst ...

    December 18, 2014
    Shares of Halozyme (HALO) jumped after announcing a worldwide collaboration and license agreement with Johnson & Johnson ...
  65. Novartis Successfully Expands Signifor Label in the U.S. - Analyst ...

    December 17, 2014
    Novartis's (NVS) Signifor long-acting release was approved in the U.S. for the acromegaly indication.
  66. Alkermes Starts Phase I Study on Schizophrenia Candidate - Analyst ...

    December 16, 2014
    Alkermes (ALKS) announced the commencement of a phase I extended dosing study on aripiprazole lauroxil for the treatment ...
  67. Acorda's Ampyra in Phase III for Post-Stroke Walking Deficit ...

    December 16, 2014
    Acorda (ACOR) has commenced a phase III study on Ampyra for the treatment of post-stroke walking deficits.
  68. Is Illumina (ILMN) Worth Adding to Your Portfolio? - Analyst ...

    December 16, 2014
    On Dec 10, 2014, we issued an updated research report on Illumina Inc. (ILMN).
  69. 4 Top Ranked Biotech Stocks that Beat the Market in 2014 - Analyst ...

    December 16, 2014
    Despite the sell-off in late March, the biotech sector bounced back thanks to important product approvals, mergers and acquisitions, ...
  70. Stock Market News for December 16, 2014 - Market News

    December 16, 2014
    Markets finished a choppy session in the negative territory on Monday as yet another slide in oil prices dented investor ...
  71. Alexion's Soliris Receives Orphan Drug Status in Japan - Analyst ...

    December 15, 2014
    Alexion (ALXN) announced that Soliris has received orphan drug designation in Japan for the treatment of myasthenia gravis.
  72. Alnylam Provides Pipeline Update, Growth Strategy - Analyst Blog

    December 15, 2014
    Alnylam (ALNY) announced a strategy for developing its RNAi therapeutics in three strategic therapeutic areas (STArs): genetic ...
  73. Jazz Pharmaceuticals Starts Defibrotide Rolling NDA Filing - ...

    December 15, 2014
    Jazz Pharmaceuticals (JAZZ) has started the rolling submission of a NDA for defibrotide.
  74. Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook

    November 18, 2014
    Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
  75. How Amgen Makes Billions On Just A Few Drugs

    November 5, 2014
    Amgen produces relatively few drugs, but that's doesn't mean it's any less essential or profitable. Here's a look at the ...
  76. Who are Amgen Inc.'s (AMGN) main competitors?

    August 27, 2014
    Biotech giant Amgen (AMGN) list of competitors is lengthy and formidable. Learn the major companies Amgen competes with.
  77. 4 Large-Cap Healthcare Stocks To Watch

    August 18, 2014
    Healthcare continues to a be a hot sector. Here are four pharma stocks to keep an eye on for entry points.
  78. S&P Down 3% - What's on Sale? - Ahead of Wall Street

    August 4, 2014
    Solid Q2 earnings across most sectors this season justified the long run-up in the stock market, and we had been expecting ...
  79. Interested In Healthcare Stocks? Look At This ETF

    July 3, 2014
    Healthcare companies seem to be poised to make a move higher over the months ahead. Here's an ETF that should be helpful ...
  80. What Are The Best Bets In Biotech?

    May 2, 2014
    The NASDAQ Biotechnology Index is off nearly 20% as its components busy themselves with hostile bids and frenzied buying ...
  81. Bull of the Day: Amgen (AMGN) - Bull of the Day

    March 31, 2014
    Bull of the Day: Amgen (AMGN) - Bull of the Day
  82. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  83. Bull of the Day: Quintiles (Q) - Bull of the Day

    March 5, 2014
    Bull of the Day: Quintiles (Q) - Bull of the Day
  84. Biotech Stock Roundup: Amgen Data Looks Good, CANF Tumbles - ...

    January 8, 2014
    Biotech Stock Roundup: Amgen Data Looks Good, CANF Tumbles - Industry Outlook
  85. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  86. 7 ETF Types To Be Thankful For

    November 28, 2013
    This year has shaped up to be quite kind to investors as major equity indexes are holding onto double-digit gains ahead of ...
  87. A Strong Prognosis For Healthcare Stocks

    November 19, 2013
    Despite the healthcare sectors recent torrid run, there’s still plenty to like about stocks in the industry. Aside from tailwinds ...
  88. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    November 12, 2013
    Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals ...
  89. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    September 14, 2013
    Declining short interest in Alexion Pharmaceuticals (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical ...
  90. Amgen Sweetens The Bid And Secures Onyx

    August 26, 2013
    Amgen finalizes a value-additive deal for Onyx
  91. Can Sanofi Investors Just Blame It On Rio?

    August 6, 2013
    Can Sanofi Investors Just Blame It On Rio? By Stephen D. Simpson, CFA Sanofi (NYSE: SNY) was supposed to be a relatively ...
  92. Does Amgen Deserve To Be Part Of The Biotech Bull Run?

    July 31, 2013
    Amgen is beating growth targets today, but fears about generics and a dull pipeline concern investors.
  93. Wall Street Happy To Hum La AbbVie En Rose

    July 26, 2013
    AbbVie's pipeline is better than some think, but valuation is no particular bargain right now.
  94. Amgen Puts Onyx Pharmaceuticals In Play

    July 2, 2013
    An unsolicited $120/share bid has sent Onyx soaring and rival bidders circling.
  95. Biotech ETFs Surge as Onyx Rejects Amgen Offer - ETF News And ...

    July 1, 2013
    Biotechnlogy ETFs are moving higher as Onyx had rejected a takeover bid by Amgen, pushing securities up across the board. ...
  96. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  97. 3 Impressive Biotech ETFs Crushing the Market - ETF News And ...

    June 11, 2013
    Rotate into the outperforming biotech sector with these three ETFs.
  98. 10 Picks from 2 Strong Sectors

    June 10, 2013
    As we enter the bumpy summer months, large-cap US domestic stocks and health-care names are on Louis Navellier's list, and ...
  99. Alnylam Basking In Orphan Drug Attention

    May 28, 2013
    Alnylam has already seen a big run, but clinical success could bring even more gains.
  100. Amgen Chased By The Bubble

    May 8, 2013
    Amgen really needs the pipeline to come through to support this valuation.
  • Showing 1-100 of 124 items
  • 1
  • 2
  • >>
Trading Center